FDA Postdoctoral Fellowship - Glyco-technology Lab

Organization

U.S. Food and Drug Administration (FDA)

FDA-CDER-

9/30/2026 3:00:00 PM Eastern Time Zone

• An application
• Transcripts – detailed information available for acceptable transcripts
• A current resume/CV, including academic history, employment history, relevant experiences, and publication list
• One educational or professional recommendation

All documents must be in English or include an official English translation.

Applications will be reviewed on a rolling basis.

Center for Drug Evaluation and Research (CDER), Office of Pharmaceutical Quality (OPQ), Office of Pharmaceutical Quality Research (OPQR), Silver Spring, Maryland.

As a postdoctoral fellow, you will join a project to research the glycan release from glycoprotein drugs with chemo-enzymatic methods and characterize glycan structures with state‑of‑the‑art technologies, including high‑performance liquid chromatography (H(U)
PLC) and mass spectrometry (MS).

Under the guidance of the mentor, you will learn and develop technologies for feasible analysis of glycosylation of therapeutic glycoprotein drugs, including monoclonal antibody drugs, fusion proteins, enzyme‑replacement therapies, plasma products, etc., in manufacturing control and characterization.

Tongzhong Ju (Tongzhong.Ju.gov)

• Start Date:
  
  2026 (flexible, dependent on funding and other factors)
• Length: one year, subject to renewal upon recommendation and availability of funds
• Full time
• Monthly stipend commensurate with educational level and experience
• Proof of health insurance required
• Background investigation required for individuals who have resided in the U.S. for a total of three of the past five years

This opportunity is available to U.S. citizens, lawful permanent residents (LPR), and foreign nationals with valid immigration statuses that are acceptable for program participation.

Participants do not become employees of FDA, DOE, or the program administrator, and there are no employment‑related benefits.

ORISE Fellows, including spouse and minor children, must report any significantly regulated organization (SRO) relationship or prohibited investment fund financial interest. Failure to divest or terminate the relationship results in ineligibility for FDA placement. For additional requirements, see FDA Ethics for Nonemployee Scientists.

• Non‑employee nature of the ORISE appointment
• Prohibition on ORISE Fellows performing inherently governmental functions
• Obligation to convey rights to FDA for intellectual property conceived or first reduced to practice during the fellowship
• Research materials and laboratory notebooks remain property of FDA
• Obligation to protect and not further disclose or use non‑public information

The qualified candidate should have received a doctoral degree in a relevant field, or be currently pursuing a doctoral degree with completion before September 29, 2026. The degree must have been received within five years of the appointment start date.

• Skills in mass spectrometry, glyco‑chemistry, and/or proteomics

Ashley

• Degree:
  Doctoral degree received within the last 60 months, or anticipated by 9/29/2026 12:00:00 AM
• Discipline(s):
  Chemistry and Materials Sciences – Analytical Chemistry, Bio‑organic Chemistry, Chemistry (General), Organic Chemistry, Polymer Chemistry;
  Life Health and Medical Sciences
• I am a U.S. citizen or have lived in the United States for at least 36 of the past 60 months
• I have read the FDA Ethics Requirements